Dynamic Technology Lab Private Ltd Sells 721 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Dynamic Technology Lab Private Ltd decreased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 10.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,226 shares of the specialty pharmaceutical company’s stock after selling 721 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Collegium Pharmaceutical were worth $241,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Gladius Capital Management LP purchased a new stake in shares of Collegium Pharmaceutical during the second quarter valued at approximately $32,000. nVerses Capital LLC lifted its position in Collegium Pharmaceutical by 1,600.0% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,600 shares in the last quarter. GAMMA Investing LLC boosted its stake in Collegium Pharmaceutical by 124.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 792 shares during the last quarter. CWM LLC increased its holdings in shares of Collegium Pharmaceutical by 97.5% in the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after purchasing an additional 736 shares in the last quarter. Finally, AXA S.A. purchased a new position in shares of Collegium Pharmaceutical in the second quarter worth $209,000.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on COLL shares. Truist Financial lifted their price objective on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 9th. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Piper Sandler restated a “neutral” rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. HC Wainwright lifted their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $42.60.

Collegium Pharmaceutical Stock Performance

COLL opened at $30.50 on Monday. The company’s 50 day moving average is $34.94 and its 200 day moving average is $34.62. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The company has a market cap of $983.63 million, a price-to-earnings ratio of 13.15 and a beta of 0.95. Collegium Pharmaceutical, Inc. has a 12-month low of $25.21 and a 12-month high of $42.29.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total transaction of $737,198.40. Following the sale, the executive vice president now owns 120,161 shares in the company, valued at approximately $4,602,166.30. This trade represents a 13.81 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the transaction, the executive vice president now owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. The trade was a 15.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.